«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年06期

页码:

647-650

栏目:

临床医学

出版日期:

2023-11-20

文章信息/Info

Title:

Correlation between improvement of lower urinary tract symptoms and metabolic syndrome after transurethral green laser enucleation of prostate

文章编号:

1006-8147(2023) 06-0647-04

作者:

宋伟航; 韩广业

（新乡医学院第一附属医院泌尿外科，新乡 453100）

Author(s):

SONG Wei-hang; HAN Guang-ye

（Department of Urology，The First Affiliated Hospital of Xinxiang Medical College，Xinxiang 453100，China）

关键词:

代谢综合征; 绿激光剜除术; 下尿路症状; 前列腺增生

Keywords:

metabolic syndrome; green laser enucleation of prostate;  lower urinary tract symptoms;  prostatic hyperplasia

分类号:

R697.32

DOI:

-

文献标志码:

A

摘要:

目的：探讨代谢综合征与经尿道前列腺绿激光剜除术后的下尿路症状的相关性。方法：选取2020年1月—2021年1月在新乡医学院第一附属医院接受经尿道前列腺绿激光剜除术患者100例，根据其是否合并有代谢综合征，将患者分为两组：代谢综合征组50例，无代谢综合征组50例。对患者的临床资料进行统计分析。并在经尿道前列腺绿激光剜除术术后半年复查泌尿系统彩超、尿流动力学、生活质量指数评分（QOL评分）、国际前列腺症状评分（IPSS）等。最后采用SPSS 21.0统计学软件对数据进行差异性分析。结果：与术前相比，两组术后的IPSS评分（t=20.506、13.609，均P＜0.05）、储尿期评分（t=19.331、10.284，均P＜0.05）、排尿期评分（t=20.710，Z=-6.163，均P＜0.05）、最大尿流率（Qmax）（Z=-6.154、-5.865，均P＜0.05）、QOL评分均有明显改善（Z=-6.227、-6.202，均 P＜0.05）。代谢综合征组术后IPSS评分（t=2.142，P＜0.05）、QOL评分（Z=-2.639，P＜0.05）和下尿路征状评分（t=2.494，Z=-3.683，均P＜0.05）高于无代谢综合征组；最大尿流率（Qmax）（t=-2.874，P＜0.05）低于无代谢综合征组。两组Qmax改善无差异（P＞0.05），但IPSS评分改善（Z=-3.171，P＜0.05）、QOL评分改善（Z=-2.522，P＜0.05）和下尿路症状改善差异明显（Z=-4.984、-6.080，均P＜0.05）。结论：代谢综合征可加重前列腺增生患者的下尿路症状。

Abstract:

Objective：To investigate the correlation between lower urinary tract symptoms and metabolic syndrome after transurethral green laser enucleation of prostate. Methods：A total of 100 patients received transurethral green laser enucleation of prostate in The First Affiliated Hospital of Xinxiang Medical University from January 2020 to January 2021 were selected. According to whether they had metabolic syndrome，the patients were divided into two groups：50 patients with metabolic syndrome and 50 patients without metabolic syndrome. The clinical data of patients were analyzed statistically. Color ultrasound，urodynamics，quality of life index（QOL） score，and international adenopathy score（IPSS） were reviewed six months after transurethral green laser enucleation of prostate. Finally，SPSS 21.0 statistical software was used to analyze the differences of the data. Results： Compared with the preoperative results，the postoperative IPSS score（t=20.506，13.609，both P＜0.05），urinary storage period score（t=19.331，10.284，both P＜0.05），urinary voiding period score（t=20.710，Z=-6.163，both P＜0.05），maximum urinary flow rate（Qmax）（Z=-6.154，-5.865，both P＜0.05） and QOL score （Z=-6.227， -6.202，both P＜0.05） of the two groups were significantly improved. The postoperative IPSS score（t=2.142，P＜0.05），QOL score（Z=-2.639，P＜0.05） and lower urinary tract symptom score（t=2.494，Z=-3.683，both P＜0.05） were higher in the metabolic syndrome group than in the non-metabolic syndrome group；the Qmax（t=-2.874，P＜0.05） was lower than that in the non-metabolic syndrome group. There was no difference in Qmax between the two groups（P>0.05），but there was significant difference in IPSS score（Z=-3.171，P＜ 0.05），QOL score（Z=-2.522，P＜0.05） and lower urinary tract symptoms（Z=-4.984，-6.080，both P＜0.05）. Conclusion：Metabolic syndrome can aggravate the symptoms of lower urinary tract in patients with prostatic hyperplasia.

参考文献/References:

[1] ZHANG F L，XU J B，SUN C M，et al. A scientometric visualization analysis for benign prostatic hyperplasia from 2016 to 2022 [J]. Urol Int，2023，107（2）：111-125.
[2] LI J Z，LI Y X，CAO D H，et al. The association between histological prostatitis and benign prostatic hyperplasia：a single-center retrospective study [J].Aging Male，2022，25（1）：88-93.
[3] BAKHAIDAR R B，HOSNY K M，MAHIER I M，et al. Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia [J]. Drug Delivery，2022，29（1）：2579-2591.
[4] TAO W，XU M，HU G，et al. Benign prostatic hyperplasia [J]. J Urology，2023，208（6）：1323-1325.
[5] NUNESR L V，ANTUNES A A，SILVINATO A，et al. Benign prostatic hyperplasia [J]. Rev Assoc Med Bras，2018，64（10）：876-881.
[6] DALMOR O F. Metabolic syndrome and urological diseases [J].Panminerva Med，2023，64（3）：314-315.
[7] IRAKOZE L，MANIRAKIZE A，ZHANG Y Q，et al. Metabolic syndrome in offspring of parents with metabolic syndrome：a meta-analysis [J]. Obesity Facts，2021，14（1）：148-162.
[8] REENA K，SANDEEP K，RAVI K. An update on metabolic syndrome：metabolic risk markers and adipokines in the development of metabolic syndrome[J]. Diabetes Metab Synd，2019，13（4）：2409-2417.
[9] GONG Y M，WANG X，LIU S，et al. Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome[J]. Int Urol Nephrol，2022， 54（9）：2125-2131.
[10] ALJEHANI A A，ALBADR N A，NASRULLAH M Z，et al. Icariin ameliorates metabolic syndrome-induced benign prostatic hyperplasia in rats [J]. Environ Sci Pollut R，2021，29（14）：20370-20378.
[11] XIA B W，ZHAO S C，CHEN Z P，et al. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume [J]. Prostate，2020，80（6）：481-490.
[12] MISRAI V，GUILLOT-TANTAY C，PASQUIE M，et al. Comparison of outcomes obtained after regular surgery versus live operative surgical cases：single-centre experience with green laser enucleation of the prostate [J]. Eur Urol Focus，2019，5（3）：518-524.
[13] MISRAI V，PASQUIE M，BORDIER B，et al. Comparison between open simple prostatectomy and green laser enucleation of the prostate for treating large benign prostatic hyperplasia：a single-centre experience [J]. World J Urol，2018，36（5）：793-799.
[14] FERRARI G，RABITO S，GATT I L，et al. Green light laser enucleation of the prostate with early apical release is safe and effective：single center experience and revision of the literature[J]. Minerva Urol Nephrol，2022，74（4）：467-474.
[15] YOUNG S，GOLZARIAN J. Prostatic artery embolization for benign prostatic hyperplasia：a review[J]. Curr Opin Urol，2018，29（3）：284-287.
[16] HO-YIN N，KAR-KEISTEFFI Y，CHI-MAN N，et al. Metabolic syndrome and benign prostatic hyperplasia：an update[J]. Asian J Urol，2018，4（3）：164-173.
[17] ZHAO S，CHEN C，CHEN Z，et al. Relationship between metabolic syndrome and predictors for clinical benign prostatic hyperplasia progression and international prostate symptom score in patients with moderate to severe lower urinary tract symptoms [J]. Urol J，2016，13（3）：2717-2726.
[18] OZER K，HORSANALI M O，GORGEL S N，et al. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio，an indicator of inflammation and metabolic syndrome[J]. Urol Int，2017，98（4）：466-471.
[19] FU Y，ZHOU Z，YANG B，et al. The relationship between the clinical progression of benign prostatic hyperplasia and metabolic syndrome：a prospective study [J]. Urol Int，2016，97（3）：330-335.

相似文献/References:

[1]郭彩云,聂秀玲,孙丽荣,等.高尿酸血症/痛风与非酒精性脂肪肝严重程度的相关研究[J].天津医科大学学报,2013,19(06):499.
　GUO Cai-yun,NIE Xiu-ling,SUN Li-rong,et al.Hyperuricemia or gout associated with the severity of nonalcoholic fatty liver disease[J].Journal of Tianjin Medical University,2013,19(06):499.
[2]高雪锦,吴存瑾,王 林,等.代谢综合征及非杓型血压与老年人右心室重构关系[J].天津医科大学学报,2014,20(04):293.
　GAO Xue-jin,WU Cun-jin,WANG Lin,et al.Relationship between right ventricular remodeling and the metabolic syndrome and non-dipper blood pressure in senior people[J].Journal of Tianjin Medical University,2014,20(06):293.
[3]张 甜,李明珍,孙丽荣,等.2型糖尿病患者代谢综合征组分与血清谷氨酰转肽酶的相关性研究[J].天津医科大学学报,2015,21(03):248.
　ZHANG Tian,LI Ming-zhen,SUN Li-rong,et al.Association of metabolism syndrome and its components with serum γ--glutamyl transpeptidase in patients with type 2 diabetes[J].Journal of Tianjin Medical University,2015,21(06):248.
[4]霍 焱,魏会宇,张 捷.辛伐他汀对代谢综合征患者血清内脂素水平的影响[J].天津医科大学学报,2015,21(05):430.
[5]李 杰 综述,刘春雨,解海杰 审校.代谢综合征与泌尿系结石关系的研究进展[J].天津医科大学学报,2017,23(06):576.
[6]吴楚姗,张聪,蒋海燕,等.甘油三酯与高密度脂蛋白-胆固醇比值在预测儿童代谢综合征中的意义[J].天津医科大学学报,2021,27(01):11.
　WU Chu-shan,ZHANG Cong,JIANG Hai-yan,et al.Significance of triglyceride to high-density lipoprotein ratio in predicting childhood metabolic syndrome[J].Journal of Tianjin Medical University,2021,27(06):11.

备注/Memo

备注/Memo:

基金项目 2022年度河南省医学科技攻关计划联合共建项目（LHGJ20220607）
作者简介 宋伟航（1990-），男，主治医师，硕士，研究方向：泌尿外科相关疾病；通信作者：韩广业，E-mail：guangye@126.com。

常用功能

更新日期/Last Update: 2023-12-01